ERBB2 and breast cancer: Doxorubicin and imatinib synergistically inhibited the viability of 435s/M14 and WM3248 melanoma cells and BT-549 triple-negative (ER−, PR−, HER-2−) breast cancer cells, and inhibited the viability of MDA-MB-468 triple-negative breast cancer cells in an additive manner (Figure 1C and S2C).